Verena Reimann1, Ursula Creutzig, Gesine Kögler. 1. Institut für Transplantationsdiagnostik und Zelltherapeutika, José Carreras Stammzellbank, Universitätsklinikum Düsseldorf, Düsseldorf, Germany. reimann@itz.uni-duesseldorf.de
Abstract
BACKGROUND: Physicians of any specialty may be the first persons to whom prospective parents turn for information about the acquisition and storage of stem cells derived from cord blood. Stem cells can potentially be used to treat many diseases, yet they are not a panacea. This article provides an overview of their current and possible future applications. METHODS: Original papers were retrieved by a selective search of the literature, and the Internet sites and advertising brochures of private stem cell banks were also examined. RESULTS: Allogeneic hematopoietic stem cells derived from umbilical cord blood (obtained from healthy donors, rather than from the patient to be treated) have been in routine use worldwide for more than ten years in the treatment of hematopoietic diseases. Experiments in cell culture and in animal models suggest that these cells might be of therapeutic use in regenerative medicine, but also show that this potential can be realized only if the cells are not cryopreserved. There is as yet no routine clinical application of autologous hematopoietic stem cells from cord blood (self-donation of blood), even though cord blood has been stored in private banks for more than ten years. CONCLUSIONS: Autologous stem cells from cord blood have poor prospects for use in regenerative medicine, because they have to be cryopreserved until use. Physicians should tell prospective parents that they have no reason to feel guilty if they choose not to store cord blood in a private bank.
BACKGROUND: Physicians of any specialty may be the first persons to whom prospective parents turn for information about the acquisition and storage of stem cells derived from cord blood. Stem cells can potentially be used to treat many diseases, yet they are not a panacea. This article provides an overview of their current and possible future applications. METHODS: Original papers were retrieved by a selective search of the literature, and the Internet sites and advertising brochures of private stem cell banks were also examined. RESULTS: Allogeneic hematopoietic stem cells derived from umbilical cord blood (obtained from healthy donors, rather than from the patient to be treated) have been in routine use worldwide for more than ten years in the treatment of hematopoietic diseases. Experiments in cell culture and in animal models suggest that these cells might be of therapeutic use in regenerative medicine, but also show that this potential can be realized only if the cells are not cryopreserved. There is as yet no routine clinical application of autologous hematopoietic stem cells from cord blood (self-donation of blood), even though cord blood has been stored in private banks for more than ten years. CONCLUSIONS: Autologous stem cells from cord blood have poor prospects for use in regenerative medicine, because they have to be cryopreserved until use. Physicians should tell prospective parents that they have no reason to feel guilty if they choose not to store cord blood in a private bank.
Authors: Ralf Sodian; Cora Lueders; Liv Kraemer; Wolfgang Kuebler; Mehdi Shakibaei; Bruno Reichart; Sabine Daebritz; Roland Hetzer Journal: Ann Thorac Surg Date: 2006-06 Impact factor: 4.330
Authors: Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: Mortimer Korf-Klingebiel; Tibor Kempf; Thomas Sauer; Eva Brinkmann; Philipp Fischer; Gerd P Meyer; Arnold Ganser; Helmut Drexler; Kai C Wollert Journal: Eur Heart J Date: 2008-10-25 Impact factor: 29.983
Authors: Karen K Ballen; Juliet N Barker; Susan K Stewart; Michael F Greene; Thomas A Lane Journal: Biol Blood Marrow Transplant Date: 2008-03 Impact factor: 5.742
Authors: Susanne Greschat; Jessica Schira; Patrick Küry; Claudia Rosenbaum; Maria Angelica de Souza Silva; Gesine Kögler; Peter Wernet; Hans Werner Müller Journal: Stem Cells Dev Date: 2008-04 Impact factor: 3.272
Authors: Sergio Querol; Ghulam J Mufti; Steven G E Marsh; Antonio Pagliuca; Ann-Margaret Little; Bronwen E Shaw; Robert Jeffery; Joan Garcia; John M Goldman; J Alejandro Madrigal Journal: Haematologica Date: 2009-02-19 Impact factor: 9.941
Authors: Mary Eapen; Pablo Rubinstein; Mei-Jie Zhang; Cladd Stevens; Joanne Kurtzberg; Andromachi Scaradavou; Fausto R Loberiza; Richard E Champlin; John P Klein; Mary M Horowitz; John E Wagner Journal: Lancet Date: 2007-06-09 Impact factor: 79.321
Authors: A Gratwohl; H Baldomero; K Frauendorfer; V Rocha; J Apperley; D Niederwieser Journal: Bone Marrow Transplant Date: 2007-12-17 Impact factor: 5.483
Authors: Louiza Z Karagiorgou; Maria-Nikoletta P Pantazopoulou; Nikolaos C Mainas; Apostolos I Beloukas; Anastasios G Kriebardis Journal: Blood Transfus Date: 2013-10-03 Impact factor: 3.443